Cheelcare Ships First Curio Robotic Wheelchairs to Paying Customers, Reports Record Companion Sales
Summary
Cheelcare Inc. has announced a significant operational milestone with the delivery of its first Curio robotic complex-rehab power wheelchairs to paying customers, signaling the start of commercial production and initial revenue generation for its flagship product. This positive development is further bolstered by record sales of its Companion units in March. The company's ability to scale production is supported by its recently completed 16,000 sq. ft. manufacturing facility, and increasing adoption is being driven by Medicare and Medicaid reimbursement. This news indicates strong market validation and a clear path to revenue growth, moving the company beyond its development phase. Traders should watch for continued sales momentum and the conversion of its growing pipeline of customer inquiries into future revenue.
At the time of this announcement, CHCRF was trading at $0.66 on OTC in the Life Sciences sector. The 52-week trading range was $0.66 to $0.66. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.